Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BIVINASDAQ:ONCYNASDAQ:RPHMNASDAQ:TRVI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$0.49$0.79$0.45▼$8.69$19.42M0.792.19 million shs530,724 shsONCYOncolytics Biotech$1.06+2.9%$1.07$0.88▼$3.39$79.95M1.93381,396 shs107,021 shsRPHMReneo Pharmaceuticals$1.74-1.1%$1.66$0.98▼$11.30$58.15M0.24280,559 shs82,987 shsTRVITrevi Therapeutics$2.84+5.6%$2.92$0.97▼$4.00$195.50M0.86281,369 shs144,331 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+3.61%-1.39%-22.38%-60.93%-94.04%ONCYOncolytics Biotech-0.96%-10.43%0.00%-14.88%-11.21%RPHMReneo Pharmaceuticals-0.56%+3.53%+6.67%+9.32%-80.31%TRVITrevi Therapeutics+4.07%-9.90%-22.40%+98.89%+9.15%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.0274 of 5 stars3.34.00.00.01.40.00.0ONCYOncolytics Biotech0.9432 of 5 stars3.53.00.00.01.30.00.0RPHMReneo Pharmaceuticals0.8678 of 5 stars2.90.00.00.00.62.51.3TRVITrevi Therapeutics2.4032 of 5 stars3.54.00.00.01.43.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie2.50Moderate Buy$8.001,544.40% UpsideONCYOncolytics Biotech3.00Buy$4.00277.36% UpsideRPHMReneo Pharmaceuticals1.88Reduce$18.14942.39% UpsideTRVITrevi Therapeutics3.00Buy$8.50199.82% UpsideCurrent Analyst RatingsLatest TRVI, RPHM, BIVI, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/19/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$0.42 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)RPHMReneo Pharmaceuticals-$77.39M-$2.52N/AN/AN/AN/A-73.14%-63.85%5/9/2024 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)Latest TRVI, RPHM, BIVI, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/19/2024N/ABIVIBioVieN/A-$0.33-$0.33N/AN/AN/A3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/A3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/A2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A1.471.47ONCYOncolytics BiotechN/A9.019.01RPHMReneo PharmaceuticalsN/A5.875.87TRVITrevi TherapeuticsN/A15.0315.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%ONCYOncolytics Biotech6.82%RPHMReneo Pharmaceuticals90.98%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipBIVIBioVie4.80%ONCYOncolytics Biotech0.10%RPHMReneo Pharmaceuticals17.90%TRVITrevi Therapeutics27.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1839.92 million38.01 millionOptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableRPHMReneo Pharmaceuticals5533.42 million27.44 millionOptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableTRVI, RPHM, BIVI, and ONCY HeadlinesSourceHeadlineTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.com - April 18 at 10:56 AMTwo stand-ups to perform at Trevi this Saturdaysaultstar.com - April 17 at 7:02 PMTrevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from Needham & Company LLCamericanbankingnews.com - April 10 at 4:14 AMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferencefinance.yahoo.com - April 9 at 9:54 AMTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferenceprnewswire.com - April 9 at 7:30 AMTrevi Therapeutics appoints new VP for clinical developmentuk.investing.com - April 4 at 7:56 PMWhy Trevi Therapeutics (TRVI) Stock Might be a Great Pickzacks.com - April 4 at 9:31 AMTrevi Therapeutics to Participate in Upcoming April Eventsprnewswire.com - April 4 at 7:30 AMTrevi piles into Melbourne’s Link megaproject with four hyrdromillsglobalconstructionreview.com - April 3 at 10:24 AMCity worker cleans coins at Trevi Fountain in Romechinaview.cn - April 2 at 8:36 PMTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Teamfinance.yahoo.com - April 2 at 10:35 AMTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itmsn.com - March 29 at 7:12 PMTrevi Italian Restaurant at Forum Shops unexpectedly closesmsn.com - March 28 at 9:44 PMProminent Trevi Italian Restaurant Abruptly Closes at the Forum Shopsmsn.com - March 27 at 1:26 PMTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 21 at 11:14 AMOppenheimer Reaffirms "Outperform" Rating for Trevi Therapeutics (NASDAQ:TRVI)marketbeat.com - March 21 at 9:38 AMTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 21 at 7:22 AMTrevi Therapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 9:21 PMTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023msn.com - March 20 at 9:21 PMTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trialsfinance.yahoo.com - March 20 at 9:21 PMGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossamsn.com - March 17 at 10:44 PMGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossamsn.com - March 16 at 4:38 PMWhat happens to the coins tossed into Rome's Trevi Fountain?astroawani.com - March 15 at 11:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Reneo PharmaceuticalsNASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.